Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 11/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377651 | 1.00 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL20032419 | 1.00 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL4008546 | 0.98 | KIF11 (0.57) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL913478 | 0.92 | KIF11 (0.59) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL4012213 | 0.84 | KIF11 (0.63) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL8714858 | 0.81 | KIF11 (0.52) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL25077100 | 0.81 | KIF11 (0.55) | KIF11HRH4TK2TK1TSHR | |
| SCHEMBL5820308 | 0.81 | KIF11 (0.55) | KIF11HRH4TK2TK1TSHR | |
| SCHEMBL21411547 | 0.81 | KIF11 (0.55) | KIF11HRH4TK2TK1TSHR | |
| SCHEMBL25077435 | 0.81 | KIF11 (0.55) | KIF11HRH4TK2TK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024179491-A1 | GBA1 AND GCS DUAL MODULATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| EP-2195310-B1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | WALLAC OY (FI) | 2016-06-01 | — | — | EP | disclosed |
| CN-101796047-B | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | WALLAC OY | 2014-12-03 | — | — | CN | disclosed |
| US-8221719-B2 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | WALLAC OY (FI) | 2012-07-17 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20100204442-A1 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | WALLAC OY (FI) | 2010-08-12 | — | — | US | disclosed |
| EP-2195310-A1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | Wallac OY (FI) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009030819-A1 | LUMINESCENT LANTHANIDE (III) CHELATES, CHELATING AGENTS AND CONJUGATES DERIVED THEREOF | WALLAC OY (FI) | 2009-03-12 | — | — | WO | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | KIF11 2729/4885HRH4 169/4885TK2 224/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | KIF11 2686/4885HRH4 179/4885TK2 259/4885 |
| US-20100204442-A1 | Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof | LNPEP, SLC39A3, LAP3 | KIF11 1726/4885HRH4 4283/4885TK2 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.